The Role of Serum VCAM-1 and TNF-α as Predictors of Mortality and Morbidity in Patients with Chronic Heart Failure

Journal of Clinical Laboratory Analysis

Volumn 27, Issue 2, 2013, Pages 105-112

  Savic Radojevic, Ana ^a   Radovanovic, Slavica ^b   Pekmezovic, Tatjana ^a   Pljesa Ercegovac, Marija ^a   Simic, Dragan ^a   Djukic, Tatjana ^a   Matic, Marija ^a   Simic, Tatjana ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b University Medical Center   (Serbia)

Author keywords

Adhesion molecules; Heart failure; Inflammation

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTERY DILATATION; ARTICLE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE EXACERBATION; ENDOTHELIUM; FEMALE; HEART FAILURE; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NEW YORK HEART ASSOCIATION CLASS; OUTCOME ASSESSMENT; PREDICTION; PROPORTIONAL HAZARDS MODEL; STATISTICAL SIGNIFICANCE;

AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHRONIC DISEASE; FEMALE; HEART FAILURE; HUMANS; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MORBIDITY; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84875619921     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.21570     Document Type: Article

References (35)

1. Anker SD, von Haehling S. Inflamatory mediators in chronic heart failure: An overview. Heart 2004;90:464-470.
2. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008;358:2148-2159.
3. Seta Y, Shan K, Bozkurt B, Oral H, Mann DL. Basic mechanisms in heart failure: The cytokine hypothesis. J Card Fail 1996;2:243-249.
4. Kofler S, Nickel T, Weis M. Role of cytokines in cardiovascular diseases: A focus on endothelial responses to inflammation. Clin Sci 2005;108:205-213.
5. Von Haehling S, Jankowska EA, Anker SD. Tumour necrosis factor-alpha and the failing heart: Pathophysiology and therapeutic implications. Basic Res Cardiol 2004;99:18-28.
6. Deswal A, Peterson NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: An analysis of the cytokine database from the Vesnarinone Trial (VEST). Circulation 2001;103:2055-2059.
7. Rodriguez-Reyna TS, Arrieta O, Castillo-Martinez L, Guevara P, Rebollar V, Granados J. Tumour necrosis factor alpha and troponin T as predictors of poor prognosis in patients with stable heart failure. Clin Invest Med 2005;28:23-29.
8. Dunlay SM, Weston SA, Redfield MM, Killian JM, Roger VL. Tumor necrosis factor-alpha and mortality in heart failure: A community study. Circulation 2008;118:625-631.
9. Devaux B, Scholz D, Hirche A, Klövekorn WP, Schaper J. Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. Eur Heart J 1997;18:470-479.
10. Madge LA, Pober JS. TNF signaling in vascular endothelial cells. Exp Mol Pathol 2001;70:317-325.
11. True AL, Rahman A, Malik AB. Activation of NF-κB induced by H2O2 and TNF-α and its effects on ICAM-1 expression in endothelial cells. Am J Physiol Lung Cell Mol Physiol 2000;279:302-311.
12. Muller WA. Mechanisms of transendothelial migration of leukocytes. Circ Res 2009;105:223-230.
13. Andreassen AK, Nordøy I, Simonsen S, et al. Levels of circulating adhesion molecules in congestive heart failure and after heart transplantation. Am J Cardiol 1998;81:604-608.
14. Tousoulis D, Homaei H, Ahmed N, et al. Increased plasma adhesion molecule levels in patients with heart failure who have ischemic heart disease and dilated cardiomyopathy. Am Heart J 2001;141:277-280.
15. Blankenberg S, Rupprecht HJ, Bickel C, et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001;104:1336-1342.
16. Pradhan AD, Rifai N, Ridker PM. Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. Circulation 2002;106:820-825.
17. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998;351:88-92.
18. Tsutamoto T, Hisanaga T, Fukai D, et al. Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure. Am J Cardiol 1995;76:803-808.
19. Yin WH, Chen JW, Jen HL, et al. The prognostic value of circulating soluble cell adhesion molecules in patients with chronic congestive heart failure. Eur J Heart Fail 2003;5:507-516.
20. Chiang MC, Yin WH, Jen HL, et al. Vascular cell adhesion molecule-1 as a prognostic marker in patients with end-stage heart failure. Acta Cardiol Sin 2004;20:94-104.
21. Jager A, van Hinsbergh VW, Kostense PJ, et al. Increased levels of soluble vascular cell adhesion molecule 1 are associated with risk of cardiovascular mortality in type 2 diabetes: the Hoorn study. Diabetes 2000;49:485-491.
22. Gustafsson JT, Simard JF, Gunnarsson I, et al. Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. Arthritis Res Ther 2012;14(2):R46 (1-11).
23. De Ciuceis C, Amiri F, Brassard P, Endemann DH, Touyz RM, Schiffrin EL. Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice: evidence for a role in inflammation in angiotensin-induced vascular injury. Arterioscler Thromb Vasc Biol 2005;25:2106-2113.
24. Cook-Mills JM. VCAM-1 signals during lymphocyte migration: Role of reactive oxygen species. Mol Immunol 2002;39:499-508.
25. Lawson C, Wolf S. ICAM-1 signaling in endothelial cells. Pharmacol Rep 2009;61:22-32.
26. Chung ES, Packer M, Lo KH, Fasanmade AA, Wilkerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure. Circulation 2003;107:3133-3140.
27. Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004;109:1594-1602.
28. Anker SD, Coats AJ. How to recover from renaissance? The significance of the results from recover, renaissance, renewal and attach. Int J Cardiol 2002;86:123-130.
29. Kaneko K, Kanda T, Yamauchi Y, et al. C-reactive protein in dilated cardiomyopathy. Cardiology 1999;91:215-219.
30. Anand IS, Latini R, Florea VG, et al. C-reactive protein in heart failure: Prognostic value and the effect of valsartan. Circulation 2005;112:1428-1434.
31. Yin WH, Chen JW, Jen HL, et al. Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am Heart J 2004;147:931-938.
32. Venugopal SK, Deveraj S, Jialal I. Effect of C-reactive protein on vascular cells: Evidence for a proinflammatory, proatherogenic role. Curr Opin Nephrol Hypertens 2005;14:33-37.
33. Torzewski M, Rist C, Mortensen RF, et al. C-reactive protein in the arterial intima: Role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000;20:2094-2099.
34. Zwaka TP, Hombach V, Torzewski J. C-reactive protein mediated low density lipoprotein uptake by macrophages: Implications for atherosclerosis. Circulation 2001;103:1194-1197.
35. Nahrendorf M, Jaffer FA, Kelly KA, et al. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation 2006;114:1504-1511.